MedTrace Logo

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-07-02

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn the effect of combining aprepitant with CHOP or R-CHOP in patients with Non-Hodgkin's Lymphoma (NHL) that is either newly diagnosed or has come back. Researchers also want to see if aprepitant can help to prevent nausea and/or vomiting that may be caused by chemotherapy treatment with CHOP or R-CHOP, in these patients. CHOP consists of four drugs - Cyclophosphamide (also called Cytoxan/Neosar), Doxorubicin (or Adriamycin), Vincristine (Oncovin) and Prednisolone while R-CHOP includes Rituximab and CHOP.

Conditions

Interventions

DRUG

Aprepitant

125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.

DRUG

Cyclophosphamide

750 mg/m\^2 By Vein On Day 1

DRUG

Doxorubicin

25 mg/m\^2 By Vein Over 48 Hours On Days 1-2

DRUG

Vincristine

2 mg By Vein On Day 1

DRUG

Prednisone

100 mg PO for 5 Days

DRUG

Rituximab

375 mg/m\^2 By Vein On Day 1.

DRUG

Ondansetron

8 mg daily for 2 days

Sponsors & Collaborators

Principal Investigators

  • Saroj Vadhan-Raj, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651755 on ClinicalTrials.gov